Search
for
Sort by
Research 181–210 of 1000+
- Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship?
- High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
- Herbs for Benign Prostatic Hyperplasia
- Role of 5 alpha-reductase inhibitors in the management of prostate cancer
- Prostate cancer and androgenic alopecia: The role of finasteride as a dual agent
- The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model
- The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth
- Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
- Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
- Prostate Cancer Early Detection, Version 2.2015
- Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships
- Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
- The Effects of Oral 5-alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model.
- Referee report. For: Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment [version 3; peer review: 2 approved]
- WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
- HPLC characterization, molecular docking, QSAR and molecular dynamics simulation of Alstonia boonei phytochemical analogs as potent 5-alpha reductase inhibitors
- Lipid Profile and 5α-Reductase Inhibition Activity of Proprietary Ultrahigh-Pressure Supercritical Carbon Dioxide and Hexane Saw Palmetto Extracts
- US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
- Risk of Poor Glycemic Control in Tamsulosin Versus Finasteride Users with Type 2 Diabetes Mellitus
- Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test
- Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
- Effects of <i>Lespedeza Cuneata aqueous extract</i> on testosterone-induced prostatic hyperplasia
- Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men
- Off-label prescriptions: patient safety first
- Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know?
- PTEN Mediates Activation of Core Clock Protein BMAL1 and Accumulation of Epidermal Stem Cells
- 5‐Alpha reductase inhibitor related litigation: A legal database review